JP2024542840A - Ｆｇｆｒ阻害剤の固体状形態 - Google Patents

Ｆｇｆｒ阻害剤の固体状形態 Download PDF

Info

Publication number
JP2024542840A
JP2024542840A JP2024534140A JP2024534140A JP2024542840A JP 2024542840 A JP2024542840 A JP 2024542840A JP 2024534140 A JP2024534140 A JP 2024534140A JP 2024534140 A JP2024534140 A JP 2024534140A JP 2024542840 A JP2024542840 A JP 2024542840A
Authority
JP
Japan
Prior art keywords
solid form
ray powder
powder diffraction
exhibiting
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024534140A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542840A5 (https=
Inventor
ダブリュー． カルドア，スティーヴン
カノーニ，トウフィケ
フィミスター，アンドリュー
ピー． レディ，ジャヤチャンドラ
ティホナス，ジョン
チョパード，シュバム
パンディ，プリータンシュ
エム． コックス，ジェイソン
カニア，ロバート
Original Assignee
キネート バイオファーマ インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キネート バイオファーマ インク． filed Critical キネート バイオファーマ インク．
Publication of JP2024542840A publication Critical patent/JP2024542840A/ja
Publication of JP2024542840A5 publication Critical patent/JP2024542840A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
JP2024534140A 2021-12-08 2022-12-07 Ｆｇｆｒ阻害剤の固体状形態 Pending JP2024542840A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163287212P 2021-12-08 2021-12-08
US63/287,212 2021-12-08
PCT/US2022/081060 WO2023107980A1 (en) 2021-12-08 2022-12-07 Solid state forms of an fgfr inhibitor

Publications (2)

Publication Number Publication Date
JP2024542840A true JP2024542840A (ja) 2024-11-15
JP2024542840A5 JP2024542840A5 (https=) 2025-12-16

Family

ID=86731361

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024534140A Pending JP2024542840A (ja) 2021-12-08 2022-12-07 Ｆｇｆｒ阻害剤の固体状形態

Country Status (12)

Country Link
US (1) US20250059170A1 (https=)
EP (1) EP4444302A4 (https=)
JP (1) JP2024542840A (https=)
KR (1) KR20240119095A (https=)
CN (1) CN118804748A (https=)
AU (1) AU2022407440A1 (https=)
CA (1) CA3239792A1 (https=)
CL (1) CL2024001679A1 (https=)
IL (1) IL313359A (https=)
MX (1) MX2024006933A (https=)
TW (1) TW202332432A (https=)
WO (1) WO2023107980A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11345681B1 (en) 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
AU2022407439A1 (en) * 2021-12-08 2024-06-27 Kinnate Biopharma Inc. Treatment of cancer with an fgfr kinase inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10124003B2 (en) * 2013-07-18 2018-11-13 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for FGFR inhibitor-resistant cancer
CN107840842A (zh) * 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
EP3969442A4 (en) * 2019-05-17 2023-08-02 Kinnate Biopharma Inc. FIBROBLAST GROWTH FACTOR RECEPTOR KINASE INHIBITORS
US11345681B1 (en) * 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases

Also Published As

Publication number Publication date
TW202332432A (zh) 2023-08-16
IL313359A (en) 2024-08-01
KR20240119095A (ko) 2024-08-06
EP4444302A1 (en) 2024-10-16
WO2023107980A1 (en) 2023-06-15
AU2022407440A1 (en) 2024-06-20
CA3239792A1 (en) 2023-06-15
CL2024001679A1 (es) 2024-11-29
US20250059170A1 (en) 2025-02-20
CN118804748A (zh) 2024-10-18
EP4444302A4 (en) 2025-09-03
MX2024006933A (es) 2024-08-26

Similar Documents

Publication Publication Date Title
US11123338B2 (en) C-met modulator pharmaceutical compositions
CN102510855B (zh) N-[3-氟-4-({6-(甲基氧基)-7-[(3-吗啉-4-基丙基)氧基]-喹啉-4-基}氧基)苯基]-n′-(4-氟苯基)环丙烷-1，1-二甲酰胺的晶形
JP7818666B2 (ja) ピリジノイルピペリジン５－ｈｔ１ｆアゴニストに関する組成物および方法
CN112423844B (zh) Rad1901-2hcl的多晶型形式
JP7825636B2 (ja) （ｓ）－ｎ－（３－（２－（（（ｒ）－１－ヒドロキシプロパン－２－イル）アミノ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－３－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびその塩の固体状態での形態
JP2024542840A (ja) Ｆｇｆｒ阻害剤の固体状形態
JP2021518375A (ja) アベマシクリブの固相形態、その使用及び調製
TWI922665B (zh) (s)-n-(3-(2-(((r)-1-羥基丙-2-基)胺基)-6-嗎啉基吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯啶-1-甲醯胺及其鹽之固態形式
CN102093387B (zh) 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物
JP2026513954A (ja) ペンタミジン類似体の多形体、製剤、およびその方法
WO2022253261A1 (zh) Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途
HK1185553B (en) C-met modulator pharmaceutical compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251208